Immuno-Oncology | Specialty

Dr. Hamid on Using Biomarkers for Immunotherapy in Melanoma

May 1st 2015

Omid Hamid, MD, chief, Translational Research and Immunotherapy, director, Melanoma Therapeutics, The Angeles Clinic and Research Institute, discusses the possibility of using biomarkers to select immunotherapy as a treatment option for patients with melanoma.

FDA Grants Priority Review to Frontline Nivolumab in Melanoma

April 30th 2015

The FDA has assigned a priority review designation to the PD-1 inhibitor nivolumab as a treatment for previously untreated patients with unresectable or metastatic melanoma.

Hodi Speaks to Significance of Phase II Data on Ipilimumab Plus Nivolumab in Melanoma

April 25th 2015

OncLive sat down with F. Stephen Hodi, director, Melanoma Center, director, Center for Immuno-Oncology, Dana-Farber Cancer Institute, to gain further insight into combination and sequencing strategies for patients with melanoma.

2015 AACR Annual Meeting Highlights

April 24th 2015

Dr. Herbst on Nivolumab for NSCLC

April 22nd 2015

Roy S. Herbst, MD, PhD, professor, Yale Cancer Center, chief of medical oncology, Smilow Cancer Hospital at Yale-New Haven, discuses the impact of the FDA's approval of nivolumab's for the treatment of squamous non-small cell lung cancer.

Adding Nivolumab to Frontline Ipilimumab Improves PFS by 60% in Melanoma

April 20th 2015

Frontline immunotherapy with nivolumab plus ipilimumab delayed disease progression by 60% compared with ipilimumab alone in patients with advanced melanoma.

Dr. Hodi on Nivolumab in Combination With Ipilimumab for Advanced Melanoma

April 20th 2015

F. Stephen Hodi, MD, discusses the results of a trial presented at the 2015 AACR Annual Meeting.

Dr. Evan Alley on KEYNOTE-028 Trial Results in Mesothelioma

April 20th 2015

Evan W. Alley, MD, PhD, discusses the results from the phase Ib KEYNOTE-028 trial on a cohort of patients with malignant pleural mesothelioma.

Pembrolizumab Nears 50% Response in High PD-L1-Expressing NSCLC

April 19th 2015

Pembrolizumab had an overall response rate (ORR) of 45.2% among a cohort of patients with PD-L1-positive non–small cell lung cancer (NSCLC) and an ORR of nearly 20% in the full population in the phase I KEYNOTE-001 trial.

Breakthrough T-Cell Therapy Halts EBV-Associated Lymphoproliferative Disorders

April 19th 2015

Infusions of Epstein-Barr virus (EBV)–specific cytotoxic T lymphocytes from healthy donors led to high response rates and significant extensions in overall survival for patients with rituximab-refractory EBV–associated lymphoproliferative disorders.

Frontline Pembrolizumab Trumps Ipilimumab in Head-to-Head Melanoma Trial

April 19th 2015

Pembrolizumab elicited significantly better outcomes compared with ipilimumab in a randomized phase III trial of patients with advanced melanoma.

Bispecific Immunotherapy Elicits Intriguing Responses in Melanoma

April 19th 2015

IMCgp100 yielded long-lasting responses in patients with advanced melanoma, according to results from a 17-patient expansion cohort presented at the 2015 AACR Annual Meeting.

Nivolumab Improves Survival in Phase III Nonsquamous NSCLC Study

April 17th 2015

Nivolumab (Opdivo) improved survival versus docetaxel in patients with pretreated nonsquamous non–small cell lung cancer in the phase III CheckMate-057 trial.

Novel Doublet and Triplet Combo Studies Explode in Melanoma

April 16th 2015

In an interview with OncLive, Jeffrey S. Weber, MD, PhD, discussed combinations currently in development for patients with advanced metastatic melanoma, and key considerations in employing the new therapies in clinical practice.

Dr. Markman on the Future of Treatment for Ovarian Cancer

April 13th 2015

Maurie Markman, MD, national director, Cancer Treatment Centers of America, discusses what he sees as future treatment paradigms in ovarian cancer.

Immunotherapy Innovator Jedd Wolchok Honored

April 11th 2015

Jedd D. Wolchok, MD, PhD, played an important role in the development of ipilimumab, the first drug to target an immune checkpoint as an anticancer strategy. He was honored in the Melanoma category with a 2014 Giants of Cancer Care® award.

Dr. Sadelain on CAR T-Cell Therapies

April 10th 2015

Michel Sadelain, MD, PhD, Director, Center for Cell Engineering and Gene Transfer and Gene Expression Laboratory, Stephen and Barbara Friedman Chair, Memorial Sloan Kettering Cancer Center (MSK), discusses chimeric antigen receptor (CAR) t-cell therapies.

Agarwala Discusses Role of Cytokines in Changing Immunotherapy Landscape

April 10th 2015

To further understand how cytokines are used in today's landscape and what their role will be in the future, OncLive interviewed Sanjiv S. Agarwala, MD, Section Chief of Hematology/Oncology, St. Luke's Cancer Center, and professor of Medicine, Temple University.

Experts Explore Immunotherapy Frontier in Melanoma

April 10th 2015

Immunotherapy advances are among the emerging treatment approaches that make it an exciting time for patients with melanoma and their physicians.

Dr. Agarwala on the Role of Cytokines in the Immunotherapy Landscape

April 2nd 2015

Sanjiv S. Agarwala, MD, Chief of Medical Oncology, Hematology, St. Luke's Cancer Center and Temple University, discusses the differences between cytokines and other types of immunotherapies.